Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-mucin-1/CD16A bispecific antibody BGB-B3227

An immunoglobulin G1 (IgG1) humanized bispecific antibody directed against the tumor associated antigen (TAA) mucin-1 (MUC1) and the human low affinity IgG Fc region receptor IIIA (FCGR3A; CD16A), with potential immunomodulating and antineoplastic activities. Upon administration, anti-MUC1/CD16A bispecific antibody BGB-B3227 targets and binds to CD16A expressed on natural killer (NK) cells and MUC1 expressed on the surface of tumor cells, thereby selectively cross-linking tumor and NK cells. This may result in NK cell activation and eventually tumor cell lysis. CD16A is specifically expressed on the surface of NK cells. MUC1, a glycoprotein overexpressed on the surface of a variety of cancer cells, plays a key role in tumor cell survival and proliferation.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-Muc1 NK cell engager BGB-B3227
anti-MUC1/CD16A bispecific antibody BGB-B3227
anti-mucin-1/anti-CD16A bispecific antibody BGB-B3227
MUC1 x CD16A bispecific antibody BGB-B3227
Code name:BGB B3227
BGB-B3227
BGBB3227
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search